YOB 1604

Drug Profile

YOB 1604

Alternative Names: YOB1604

Latest Information Update: 22 Jan 2016

Price : $50

At a glance

  • Originator Yungjin Pharm Co
  • Class Urologics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia

Most Recent Events

  • 22 Jan 2016 Discontinued - Phase-I for Benign prostatic hyperplasia in South Korea (PO) prior to January 2016 (Yungjin Pharm's pipeline, January 2016)
  • 15 Jul 2014 Phase-I clinical trials in Benign prostatic hyperplasia in South Korea (PO) prior to July 2014 (Yungjin Pharm's pipeline, July 2014)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top